RECTIFY-1NCT07735624
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
At risk: Primary completion moved 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 48 words Show 4 more changesShow less
- Primary completion pushed from Jan 1, 2027 to Jun 1, 2027
- Start date changed from estimate of Sep 2026 to Aug 10, 2026
- Secondary endpoints: details revised at 4 of 6 entries
- Site details revised at 1 of 3 sites
- Notable Recruitment opened
- Site details revised at 3 of 3 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Complete response (cCR plus nCR with pCR at resection) within 6 months from initiation of therapy or nCR with pathologic complete response (pCR) with TES
Timeframe: From baseline to 6 months from initiation of therapy
Secondary (6)
Incidence of treatment-emergent adverse events
Incidence of surgical complications
Organ preservation rate
3-year locoregional recurrence rate
Disease-free survival
Show 1 moreShow less
Overall survival
Arms and interventions
Botensilimab + BalstilimabExperimental
Participants receive: * Botensilimab: one IV infusion on Cycle 1 Day 1, over about 30 minutes * Balstilimab: IV infusion every 2 weeks on Day 1 of each treatment cycle, over about 30 minutes, for up to 6 months The protocol specifies: * Botensilimab dose: 75 mg IV once * Balstilimab dose: 240 mg IV every 2 weeks for up to 6 months
Drugs: Botensilimab, Balstilimab
Sites
3 sites in 1 country